As part of a worldwide initiative, a leading pharmaceutical company wanted to better understand early disease risks and gauge the potential for prevention. The client tasked SPRIM with identifying which diseases offered enough clinical data to enable clear risk identification and effective intervention prior to disease onset.
Due to the identified biomarkers and surprising comorbidity data, a specific cardiovascular event (CE) was chosen as the first opportunity for intervention.
SPRIM partnered with a concierge medicine group to obtain retrospective patient biomarker and outcome data.
SPRIM’s big data team leveraged select biomarkers to create an algorithm that identified patients at elevated risk for the specific CE.
In parallel, SPRIM leveraged peer-reviewed scientific studies to create a suite of interventions to decrease CE risk based on biomarker profile.
SPRIM was engaged for implementation of the program to identify operational healthcare and digital partners, as well as target patient outlets to streamline execution.
